Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Activated factor IX"'
Publikováno v:
Expert Opinion on Drug Safety. 20:387-396
Emicizumab is a bispecific-humanized monoclonal antibody that improves hemostasis by bridging activated factor IX and factor X to substitute for the function of missing activated FVIII. It is an alternative to prophylaxis with factor VIII replacement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f90ba918405fef8c7c63d37ec523e2d
https://doi.org/10.1080/14740338.2021.1893303
https://doi.org/10.1080/14740338.2021.1893303
Autor:
Osterud, Bjarne, Rapaport, Samuel I.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 1977 Dec 01. 74(12), 5260-5264.
Externí odkaz:
https://www.jstor.org/stable/67333
Autor:
Johannes Oldenburg, Víctor Jiménez-Yuste, Gallia G. Levy, M Elisa Mancuso, Willem Bujan, Christine L. Kempton, Elina Asikanius, Joanne I. Adamkewicz, Christophe Dhalluin, Markus Niggli, Midori Shima, Ido Paz-Priel, Michael U. Callaghan, Claude Negrier, Johnny Mahlangu, Christophe Schmitt, Rebecca Kruse-Jarres
Publikováno v:
New England Journal of Medicine. 379:811-822
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. In a phase 3, multicenter trial, we investigated its use as prophylax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8035a931d76a4d61207cd59b879b59f7
https://doi.org/10.1056/nejmoa1803550
https://doi.org/10.1056/nejmoa1803550
Autor:
Rene van Oerle, Hugo ten Cate, Dennis W Nilsen, Thomas Lindner, Henri M. H. Spronk, Harry Staines, Hildegunn Aarsetoey, Reidun Aarsetoey
Publikováno v:
Circulation. 140
Introduction: Sudden cardiac arrest (SCA) and cardiopulmonary resuscitation (CPR) are associated with activated coagulation and impairment of end-organ perfusion. Activated factor IX (FIXa) is part of the intrinsic coagulation system. FIX may also be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af55c86393732e3e2a481d05d600077a
https://doi.org/10.1161/circ.140.suppl_2.136
https://doi.org/10.1161/circ.140.suppl_2.136
Publikováno v:
Current opinion in pharmacology. 45
In this Pharmacological Perspective, we discuss the fast innovation currently occurring in the field of hemophilia. On the background of standard therapy, which includes plasma-derived and recombinant products, a first wave of innovation was represen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab6ecd8516391f2ae1cbd47cb4093606
https://pubmed.ncbi.nlm.nih.gov/31331868
https://pubmed.ncbi.nlm.nih.gov/31331868
Autor:
Krzysztof Plens, Anetta Undas, Danuta Czarnecka, Piotr Kusak, Matthew Gissel, Saulius Butenas
Publikováno v:
Archives of Medical Science : AMS
Introduction: Previously, we have demonstrated that significant proportions of patients with various cardiovascular diseases have active tissue factor and active factor XIa in their plasma. In the current study, we evaluated active tissue factor and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87e1030116f7cce4d23a975b2c9b9643
https://doi.org/10.5114/aoms.2015.54791
https://doi.org/10.5114/aoms.2015.54791
Autor:
Donna DiMichele
Publikováno v:
New England Journal of Medicine. 374:2087-2089
Hemophilia A is an X-linked hemorrhagic disorder characterized by a congenital absence or decrease in plasma clotting factor VIII, a procoagulation cofactor and potent generator of thrombin when bound to activated factor IX and factor X. Unprecedente
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0a6e404fc5e3349eed60d7a6c36bf52
https://doi.org/10.1056/nejme1603419
https://doi.org/10.1056/nejme1603419
Autor:
David M. Stern, Giora Z. Feuerstein
Publikováno v:
Drug Discovery Today: Therapeutic Strategies. 2:279-283
Thrombosis is the leading cause of death from heart attacks and strokes. Warfarin (coumadin), the only marketed oral anticoagulant provides limited efficacy with significant bleeding liabilities, monitoring and management needs. Thrombin and activate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed7a8929f7e1ce69e4d9636594c186b5
https://doi.org/10.1016/j.ddstr.2005.08.013
https://doi.org/10.1016/j.ddstr.2005.08.013
Autor:
Valder R. Arruda
Publikováno v:
Haematologica. 100:849-850
Activated factor IX and its cofactor, activated factor VIII, are critical for the proteolytic activation of factor X. Inherited deficiencies of these factors cause the bleeding disorders hemophilia B and hemophilia A, respectively. The development of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1939833120fab4a8c26d306d629f0bc
https://doi.org/10.3324/haematol.2015.129858
https://doi.org/10.3324/haematol.2015.129858
Publikováno v:
Thrombosis and Haemostasis. 79:778-783
SummaryA very sensitive and highly reliable test system for the detection of activated coagulation factor IX (FIXa) has been established. This assay system is based on the cleavage of a fluorogenic substrate by activated factor X (FXa) which is gener
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::934fd2c6a61f4c100391af8ca6332fcd
https://doi.org/10.1055/s-0037-1615064
https://doi.org/10.1055/s-0037-1615064